Boya Biological: In the future, research will focus on areas such as gene therapy and antibody drugs.

In response to the question "Apart from blood products, does the company have any other research projects?", Bioyabio stated on the interactive platform on February 25 that in recent years, the company has successfully launched products such as PCC, Factor VIII, high-concentration intravenous human immunoglobulin, and tetanus immunoglobulin, placing the number of products at the forefront of the industry. Currently, the company's research pipeline includes products such as immunoglobulin, coagulation factors, and trace proteins, with projects in the clinical stage including C1 esterase inhibitor, 20% subcutaneous injection of human immunoglobulin, and human coagulation factor IX. In the future, the company will focus on research in the field of gene therapy, antibody drugs, and other areas to further broaden its product structure and enhance its core competitiveness.